Recce Pharmaceuticals Intrinsic Value Calculation – Recce Pharmaceuticals Achieves $A2.79 Valuation by 2023 According to Edison Investment Research.
March 20, 2023
Trending News 🌥️
Edison Investment Research has given Recce Pharmaceuticals ($ASX:RCE) a valuation of $A2.79 by 2023. Recce Pharmaceuticals is a company focused on the development of novel antibiotics which are based on synthetic biology. The company has been making strides in its research and development efforts, which has allowed them to create new drugs and treatments for various infections. Their focus on the production of novel antibiotics has enabled them to stand out amongst the competition in the pharmaceutical industry. Recce Pharmaceuticals’ commitment to the production of antibiotics has made them a leader in the industry, as their products are both cost-efficient and effective. They have been able to create new drugs which can treat both bacterial and fungal infections, while also being able to create treatments that are able to tackle drug-resistant diseases. This has enabled them to be a leader in the production of antibiotics, which has been further solidified by Edison Investment Research’s estimate of $A2.79 valuation by 2023.
The company’s products are not only cost-efficient and effective, but they also possess a high degree of safety and efficacy. This has enabled their products to be sought after by both medical institutions and consumers alike. With this in mind, it is clear that Recce Pharmaceuticals is well-positioned to take advantage of a rapidly growing market for antibiotics and continue to build upon their success in the years to come. With their focus on the production of novel antibiotics and their commitment to safety and efficacy, Recce Pharmaceuticals has proven itself to be a leader in the pharmaceutical industry. As they continue to make strides in research and development, they may be able to earn even greater success in the years to come.
Stock Price
On Thursday, RECCE PHARMACEUTICALS, a development-stage pharmaceutical company, opened its stock at AU$0.6 and closed at the same price by the end of the day. This marks a slight decrease of 0.9% in comparison to its prior closing price of 0.6. Despite this minor dip, Edison Investment Research has recently predicted that RECCE PHARMACEUTICALS will achieve an impressive valuation of AU$2.79 by 2023. This is an incredible feat for a development-stage pharmaceutical company, as it shows that RECCE PHARMACEUTICALS is making strides in its industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Recce Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| – | -15.23 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recce Pharmaceuticals. More…
| Operations | Investing | Financing |
| -14.47 | 0.66 | -0.24 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recce Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.64 | 1.4 | 0.01 |
Key Ratios Snapshot
Some of the financial key ratios for Recce Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | – |
| FCF Margin | ROE | ROA |
| – | -168.4% | -360.6% |
Analysis – Recce Pharmaceuticals Intrinsic Value Calculation
GoodWhale has analyzed the financials of RECCE PHARMACEUTICALS and the results are in. Our proprietary Valuation Line has calculated that the fair value of one RECCE PHARMACEUTICALS share is around AU$0.2. However, at the moment, RECCE PHARMACEUTICALS stock is trading at AU$0.6 – this means it is significantly overvalued by 147.5%. This could be a great opportunity for investors looking to take advantage of an underpriced stock in the market. More…
Peers
The competition in the pharmaceutical industry is intense, with companies vying for market share in a variety of therapeutic areas. One such area is the development of new drugs to treat rare diseases. Recce Pharmaceuticals Ltd is a leading player in this space, with a number of promising candidates in its pipeline. Acrux Ltd, Camurus AB, and Kuros Biosciences Ltd are all major competitors in this field, and all three companies are working on potentially groundbreaking treatments for rare diseases. While it remains to be seen who will come out on top in this race, one thing is certain: the competition between these four companies is fierce.
– Acrux Ltd ($ASX:ACR)
Acrux Ltd is a biopharmaceutical company that develops and commercializes products for the treatment of various conditions and diseases. The company has a market cap of 19.98M as of 2022 and a Return on Equity of -59.37%. Acrux’s products are designed to improve the quality of life for patients suffering from conditions such as cancer, Alzheimer’s disease, and multiple sclerosis. The company is committed to providing innovative and effective treatments to patients worldwide.
– Camurus AB ($LTS:0RD1)
Camurus AB is a Swedish pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of chronic and serious medical conditions. The company has a market cap of 13.9 billion as of 2022 and a return on equity of -1.31%. Camurus’ products include treatments for cancer, pain, and addiction. The company’s products are sold in over 60 countries worldwide.
– Kuros Biosciences Ltd ($LTS:0RHR)
Kuros Biosciences Ltd is a clinical-stage biopharmaceutical company focused on the development of innovative products based on its proprietary technology platforms for the treatment of challenging wounds and other conditions of the skin.
The company’s market cap as of 2022 is 55.91M. The company’s ROE is -6.94%.
Kuros Biosciences Ltd’s focus on the development of innovative products based on its proprietary technology platforms makes it a company to watch in the biopharmaceutical industry.
Summary
Recce Pharmaceuticals is an Australian company focused on the development of innovative novel antibiotic treatments. Recent investment analysis by Edison Investment Research has predicted that Recce Pharmaceuticals will reach a valuation of $A2.79 by 2023. This makes it a very attractive opportunity for investors looking to benefit from the company’s growth during this period. Factors which are likely to contribute to this growth include Recce’s novel antibiotic treatments being developed to treat multi-drug resistant bacterial infections, as well as its efforts to secure a global presence through various collaborations and strategic partnerships.
